DZ BANK/PUT/GILEAD SCIENCES/80/0.1/16.01.26 | Market Closed - Börse Stuttgart 02:03:06 2024-07-12 EDT | ||
| 1.42 EUR | -4.05% |
|
| Current month | -5.33% | ||
| 1 month | -20.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 1.42 | -4.05% |
| 24-07-11 | 1.48 | -3.90% |
| 24-07-10 | 1.54 | -1.91% |
| 24-07-09 | 1.57 | +3.97% |
| 24-07-08 | 1.51 | -7.93% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 02:03 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | DZ BANK |
| WKN | DJ80VT |
| ISIN | DE000DJ80VT8 |
| Date issued | 2024-01-30 |
| Strike | 80 $ |
| Maturity | 2026-01-16 (551 Days) |
| Parity | 10 : 1 |
| Emission price | 0.77 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.92 € |
|---|---|
| Lowest since issue | 1.02 € |
| Spread | 0.01 € |
| Spread % | 0.70% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.96
USD
Average target price
83.08
USD
Spread / Average Target
+18.75%
- Stock Market
- Warrants
- Warrant
